Chemomab Therapeutics (CMMB) Operating Income (2017 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Operating Income came in at $3.9 million in Q3 2019, up 55.57% YoY from $2.5 million in Q3 2018, and down 12.29% on a QoQ basis from $4.4 million in Q2 2019.
Chemomab Therapeutics (CMMB) Operating Income (2017 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has 3 years of Operating Income data on file, last reported at $3.9 million in Q3 2019.
- Quarterly Operating Income rose 55.57% year-over-year to $3.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $16.8 million (up 40.17% YoY) and the FY2018 annual result came in at -$13.0 million, down 38.88% from the prior year.
- Operating Income declined to $3.9 million in Q3 2019, from $4.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $5.4 million in Q1 2019 to a low of $1.9 million in Q4 2017.
- A 3-year average of $3.6 million and a median of $3.6 million in 2018 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 59.78% in 2019, down 6.75% in 2019.
- Tracing CMMB's Operating Income over 3 years: stood at $1.9 million in 2017, then soared by 58.13% to $3.0 million in 2018, then surged by 30.95% to $3.9 million in 2019.
- The last three Operating Income figures came in at $3.9 million (Q3 2019), $4.4 million (Q2 2019), and $5.4 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 133.12 Mn |
| 10 | Chemomab Therapeutics | 13.27 Mn | 2.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 3.90 Mn |
| Jun 30, 2019 | 4.44 Mn |
| Mar 31, 2019 | 5.43 Mn |
| Dec 31, 2018 | 2.98 Mn |
| Sep 30, 2018 | 2.51 Mn |
| Jun 30, 2018 | 4.16 Mn |
| Mar 31, 2018 | 3.40 Mn |
| Dec 31, 2017 | 1.88 Mn |